Barclays’s CureVac CVAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,609
| Closed | -$11.8K | – | 5118 |
|
|
2025
Q4 | $11.8K | Sell |
2,609
-11,654
| -82% | -$59.7K | ﹤0.01% | 4921 |
|
|
2025
Q3 | $76.9K | Sell |
14,263
-25,930
| -65% | -$140K | ﹤0.01% | 4677 |
|
|
2025
Q2 | $218K | Buy |
40,193
+1,949
| +5% | +$7.73K | ﹤0.01% | 4217 |
|
|
2025
Q1 | $106K | Buy |
38,244
+3,408
| +10% | +$11.9K | ﹤0.01% | 4384 |
|
|
2024
Q4 | $119K | Buy |
34,836
+11,890
| +52% | +$34.3K | ﹤0.01% | 4553 |
|
|
2024
Q3 | $67.5K | Buy |
+22,946
| New | +$75.6K | ﹤0.01% | 4677 |
|
|
2024
Q2 | – | Sell |
-12,289
| Closed | -$37.2K | – | 4951 |
|
|
2024
Q1 | $37.2K | Sell |
12,289
-80,928
| -87% | -$284K | ﹤0.01% | 4674 |
|
|
2023
Q4 | $392K | Sell |
93,217
-4,429
| -5% | -$24K | ﹤0.01% | 4025 |
|
|
2023
Q3 | $667K | Sell |
97,646
-19,296
| -17% | -$170K | ﹤0.01% | 2614 |
|
|
2023
Q2 | $1.22M | Buy |
116,942
+16,782
| +17% | +$150K | ﹤0.01% | 2180 |
|
|
2023
Q1 | $698K | Sell |
100,160
-25,090
| -20% | -$219K | ﹤0.01% | 3009 |
|
|
2022
Q4 | $755K | Buy |
125,250
+54,195
| +76% | +$400K | ﹤0.01% | 3029 |
|
|
2022
Q3 | $561K | Sell |
71,055
-32,951
| -32% | -$384K | ﹤0.01% | 2628 |
|
|
2022
Q2 | $1.42M | Buy |
104,006
+22,161
| +27% | +$367K | ﹤0.01% | 2090 |
|
|
2022
Q1 | $1.61M | Buy |
+81,845
| New | +$1.63M | ﹤0.01% | 2037 |
|
Barclays's CVAC Position: Q1 2026 in Review
Barclays sold out of CureVac (CVAC) in Q1 2026, closing a stake of 2,609 shares — an estimated $11.8K sold.
Barclays first reported a position in CVAC in Q1 2022 and held it in 15 quarters. The position peaked at $1.61M in Q1 2022. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.
- Barclays reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
- Barclays sold 2,609 CureVac shares in Q1 2026, an estimated $11.8K.
- Barclays first reported a position in CureVac in Q1 2022 and held it in 15 quarters.
- Barclays's CureVac position peaked at $1.61M in Q1 2022.
- 0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.